scorecardresearch
Add as a preferred source on Google
Thursday, April 30, 2026
TopicMounjaro

Topic: Mounjaro

Mounjaro or Ozempic? What 1st study on Indian cohort found out about efficacy of anti-obesity drugs

Published in Indian Journal of Endocrinology and Metabolism, the study finds that patients without diabetes lost more than double the weight compared to those with the condition.

Why US drugmaker Eli Lilly is warning against compounded tirzepatide mixed with vitamin B12

Tirzepatide is the active ingredient in Lilly’s popular anti-obesity & diabetes drugs, Mounjaro & Zepbound. Experts say the matter has little relevance for India at present.

Indian middle class is fed up with being paunchy and plump. Ozempic and Mounjaro are big hits

The instant success of weight loss drugs in India tells us how quickly the country is changing. And for once, the change is for the better.

Obesity care in India is evolving—no longer just diets & surgery, it’s all about multi-specialty approach

As obesity management draws awareness and weight-loss injections are launched in India, hospitals are offering customised multidisciplinary treatments, at a cost.

In battle for Indian anti-obesity market, Eli Lilly’s pre-filled pen on one side, Novo Nordisk’s on other

India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore & is projected to grow nearly eightfold by 2030, according to market estimates.

Mounjaro vs Wegovy: Guess which obesity drug outperformed the other by a mile in head-to-head trial

Both medications were prescribed as weekly injections for patients clinically classified as obese, and were recommended alongside a controlled diet and regular physical activity.

Mounjaro will shrink India’s appetite for packaged food, gyms, weight loss supplements

The pharmaceutical world’s latest blockbuster isn’t just changing waistlines but reshaping entire industries.

Big buzz over Mounjaro launch but here’s why India’s anti-obesity drug market may only take off next yr

India’s obesity crisis fuels a $2.6 bn drug race as pharma firms rush to launch affordable semaglutide generics, aiming to transform access to weight-loss treatment.

On Camera

New promo video by PLA Navy is a teaser of China’s deep blue capabilities

Rather than functioning as conventional propaganda, the video operates as a device for interpretation, subtly shaping expectations about future developments in China’s naval trajectory.

Adani’s giant copper plant hits technical setbacks in first year

The 500,000 tonne-per-year plant produced just 94,000 tonnes of refined copper from April 2025 to February this year.

Indian drone tech company ideaForge signs MoU with Japanese firm to develop next-gen AI powered drones

By pairing Indian drone engineering with Japanese semiconductor expertise, the two firms aim to develop more advanced autonomous systems tailored to both defence & commercial use.

Trump, Netanyahu’s Iran gamble: The regime change rebound

American objectives are unmet. They neither have muscle nor motivation to resume the war. As for Iran, the regime didn’t just survive, it’s now led by more radical individuals.